EP1240329A2 - i STREPTOCOCCUS PNEUMONIAE /i ANTIGENS - Google Patents
i STREPTOCOCCUS PNEUMONIAE /i ANTIGENSInfo
- Publication number
- EP1240329A2 EP1240329A2 EP00977771A EP00977771A EP1240329A2 EP 1240329 A2 EP1240329 A2 EP 1240329A2 EP 00977771 A EP00977771 A EP 00977771A EP 00977771 A EP00977771 A EP 00977771A EP 1240329 A2 EP1240329 A2 EP 1240329A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- pneumoniae
- antigenic fragment
- nucleic acid
- sds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims abstract description 16
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims abstract description 16
- 239000000427 antigen Substances 0.000 title description 8
- 102000036639 antigens Human genes 0.000 title description 8
- 108091007433 antigens Proteins 0.000 title description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 137
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 137
- 230000000890 antigenic effect Effects 0.000 claims abstract description 26
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 229960005486 vaccine Drugs 0.000 claims abstract description 13
- 238000003745 diagnosis Methods 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000012634 fragment Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000005571 anion exchange chromatography Methods 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- VBKIFHUVGLOJKT-FKZODXBYSA-N Asn-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)N)O VBKIFHUVGLOJKT-FKZODXBYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- IOUPEELXVYPCPG-UHFFFAOYSA-N Valylglycine Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 239000008188 pellet Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 238000011176 pooling Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 11
- 210000002421 cell wall Anatomy 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 101710093560 34 kDa protein Proteins 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000006161 blood agar Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000001986 peyer's patch Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YYPNLXNMXQFMHG-GSEHKNNPSA-N (3r,5s,8s,9s,10s,13s,14s,17s)-17-acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one;[2-[(3r,5s,8s,9s,10s,13s,14s,17s)-3-hydroxy-10,13-dimethyl-11-oxo-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahyd Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O.C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)COC(=O)C)[C@@]2(C)CC1=O YYPNLXNMXQFMHG-GSEHKNNPSA-N 0.000 description 2
- 101710097567 12 kDa protein Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 101710164418 Movement protein TGB2 Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000007195 tryptone soya broth Substances 0.000 description 2
- 101710154545 16 kDa protein Proteins 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- VMXLZAVIEYWCLQ-UHFFFAOYSA-N 4-(4-aminophenyl)-3-methylaniline Chemical compound CC1=CC(N)=CC=C1C1=CC=C(N)C=C1 VMXLZAVIEYWCLQ-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 101150078806 BCAT2 gene Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 102100026413 Branched-chain-amino-acid aminotransferase, mitochondrial Human genes 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- -1 elixirs Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000310 rehydration solution Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960004175 xylazine hydrochloride Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
Definitions
- FIGURE 1 is a flow chart with a schematic summary of the protein purification procedure used in the present invention.
- FIGURE 6 is a histogram showing pulmonary clearance following immunisation with S. pneumoniae protein of 34 kDa.
- the lungs were removed following lavage, placed in 2mL sterile PBS and homogenised.
- the lung homogenate was assessed by plating 10-fold serial dilutions onto blood agar for CFU determination. Results are presented only for the proteins which showed significant degrees of pulmonary clearance from the lungs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to an antigenic protein derived from Streptococcus pneumoniae. The protein is antigenic and is useful in the preparation of vaccines and the diagnosis of S. pneumoniae infection.
Description
STREPTOCOCCUS PNEUMONIAE ANTIGENS
The present application relates to a protein which is derived from Streptococcus pneumoniae, in particular to a cell wall protein. The invention also relates to the use of this protein in medicine, particularly in the prophylaxis and diagnosis of
Streptococcus pneumoniae infection.
Respiratory diseases remain a major cause of morbidity and mortality throughout the world. Streptococcus pneumoniae is a major causative pathogen in the respiratory tract. Infections caused by this pathogen include otitis media, lower respiratory tract infections, bacteremia and meningitis.
The burden of disease caused by these pathogens is highly significant and contributes significantly to national health budgets. Although there is a vaccine available for Streptococcus pneumoniae, this vaccine is not highly efficacious in children under two years. Current therapy relies on antibiotic treatment of the infection. Many suffering from infections caused by Streptococcus pneumoniae live in developing countries, where some communities have very limited access to adequate medical treatment. Thus, antibiotic treatment may not be available. In the developed world, where antibiotics are available, there has been a significant emergence of antibiotic resistance in these bacteria.
The development of an effective vaccine against S. pneumoniae is therefore a desirable objective. In particular, it is desirable to develop a vaccine which can be used in young children.
The development of an effective vaccine against S. pneumoniae involves identification of highly conserved protective antigens and an understanding of the immune response.
The present inventors have isolated and purified a protein from the cell wall of S. pnuemoniae. This protein is of use as a vaccine and also in the diagnosis of S. pneumoniae infection.
Therefore, in a first aspect of the present invention, there is provided a protein derived from Streptococcus pneumoniae or a homologue thereof or an antigenic fragment of the protein or homologue, wherein the protein has a molecular weight of about 34 kDa as determined by SDS-PAGE under reducing conditions and has the following amino terminal sequence:
V X X V G I N T X S X X Q S
(Val X X Val Gly He Asn Thr X Ser X X Gin Ser) (SEQ ID NO: 1);
wherein X represents an unknown amino acid residue.
The protein of the present invention is isolatable from S. pneumoniae and may be provided in substantially pure form. For example, it may be provided in a form which is substantially free of other proteins.
As discussed herein, the protein of the invention is useful as antigenic material. Such material can be "antigenic" and/or "immunogenic". Generally, "antigenic" is taken to mean that the protein is capable of being used to raise antibodies or indeed is capable of inducing an antibody response in a subject. "Immunogenic" is taken to mean that the protein is capable of eliciting a protective immune response in a subject. Thus, in the latter case, the protein may be capable of not only generating an antibody response but, in addition, non-antibody based immune responses.
The skilled person will appreciate that homologues or derivatives of the protein or polypeptide of the invention will also find use in the context of the present invention, i.e. as antigenic/immunogenic material. Thus, for instance proteins or polypeptides
which include one or more additions, deletions, substitutions or the like are encompassed by the present invention. In addition, it may be possible to replace one amino acid with another of similar "type". For instance replacing one hydrophobic amino acid with another. One can use a program such as the CLUSTAL program to compare amino acid sequences. This program compares amino acid sequences and finds the optimal alignment by inserting spaces in either sequence as appropriate. It is possible to calculate amino acid identity or similarity (conservation of amino acid type) for an optimal alignment. A program like BLASTx will align the longest stretch of similar sequences and assign a value to the fit. It is thus possible to obtain a comparison where several regions of similarity are found, each having a different score Both types of analysis are contemplated in the present invention.
In the case of homologues, the degree of identity with a protein as described herein is less important than that the homologue should retain its antigenicity and/or immunogenicity to S. pneumoniae. However, for the purposes of the present invention, a protein sequence may be regarded as substantially homologous to another protein sequence if a significant number of the constituent amino acids exhibit homology when using the one of the algorithms mentioned above. At least 40%, 50,%, 60%, 70%, 80%, 90%, 95% or even 99%, in increasing order of preference, of the amino acids, may be homologous or identical.
It is well known that is possible to screen an antigenic or immunogenic protein or polypeptide to identify epitopic regions, i.e. those regions which are responsible for the protein or polypeptide' s antigenicity or immunogenicity. Methods well known to the skilled person can be used to test fragments and/or homologues and/or derivatives for antigenicity. Thus, the fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties. Thus, for fragments according to the present invention, the degree of identity is perhaps irrelevant, since they may be 100% identical to a particular part of a protein or polypeptide, homologue or derivative as described
herein. The key issue, once again, is that the fragment retains the antigenic/immunogenic properties of the protein from which it is derived. The invention provides a protein comprising an antigenic fragment as defined above.
In this specification, the molecular weight of the protein has been measured by SDS- PAGE under reducing conditions. As one skilled in the art will appreciate, Lie molecular weight values obtained by this method are accurate only to a degree of about ± 20% and are dependent upon the particular gel and molecular weight markers which are used.
In a further aspect of the invention, there is provided a process for the preparation of an isolated and purified protein, the process comprising the following steps:
(a) preparing cultures of S. pneumoniae, growing the cultures under appropriate conditions and harvesting them, followed by washing with centrifugation to yield a washed cell pellet;
(b) resuspending the washed cells in an appropriate buffer followed by disruption of the cells;
(c) centrifuging to remove cell debris and obtaining the supernatant containing soluble cell proteins;
(d) subjecting the solution obtained to anion exchange chromatography with a sodium chloride gradient elution, and pooling the fractions corresponding to each separate peak;
(e) suspending the protein fractions in a buffer comprising 0.5M Tris HC1 pH 6.8; 10%(v/v) glycerol; 10% (w/v) SDS; 0.05% (w/v) bromophenol blue; and 0.05% (v/v)
β-mercaptoethanol; boiling the mixture and then purifying by SDS-PAGE using a 12% (w/v) acrylamide/BIS separating gel with a 4% (w/v) acrylamide/BIS stacking gel, run at 16 mA in the stacking gel and 24 mA in the resolving gel;
(f) selecting a fraction containing a protein having a molecular weight of 34kDa and isolating the protein from the selected fraction.
Alternatively, the protein may be prepared by expressing the appropriate nucleic acid.
Therefore, in a further aspect of the present invention, there is provided an isolated or recombinant nucleic acid encoding a protein of the first aspect of the invention or antigenic fragment thereof or a nucleic acid complementary thereto.
For the purposes of expression, the nucleic acid, which may be DNA, may be inserted into a vector, which may be a plasmid, cosmid or a phage. The vector may be incorporated into the genome of a host organism, which may be either a prokaryotic or a eukaryotic organism.
The nucleic acid or vector may be suitable for expressing the protein of the present invention in a subject to be treated, i.e. it may be in the form of a so-called DNA vaccine. Methods and agents suitable for the preparation of a DNA vaccine are well known to the skilled person.
The protein or fragments thereof may be useful in a method for the prophylaxis of S. pneumoniae infection, the method comprising administering to a patient in need of such treatment an effective amount of the protein or fragment thereof. The invention also provides a method of vaccinating a subject against S. pneumoniae which comprises the step of administering to the subject an effective amount of protein or antigenic fragment as defined above.
The protein is also useful for diagnosing S pneumoniae infection.
Therefore, in a further aspect of the present invention, there is provided a protein derived from Streptococcus pneumoniae or a homologue thereof or an antigenic fragment of the protein or homologue, or nucleic acid coding therefor, for use in medicine, particularly in the prophylaxis or diagnosis of infection by S. pneumoniae, wherein the protein has a molecular weight of about 34 kDa as determined by SDS- PAGE under reducing conditions and has the following amino terminal sequence:
V X X V G I N T X S X X Q S
(Val X X Val Gly He Asn Thr X Ser X X Gin Ser) (SEQ ID NO: 1)
wherein X represents an unknown amino acid residue.
In addition to the prophylaxis of infection by S. pneumoniae, the protein of the present invention is also of use in the diagnosis of such infection. Thus, a further aspect provides a method of detecting and/or diagnosing S. pneumoniae which comprises:
(a) bringing into contact with a sample to be tested a protein as defined above or a homologue thereof or an antigenic fragment of the protein or homologue; and
(b) detecting the presence of antibodies to S pneumoniae.
In a further aspect of the invention, there is provided the use of a protein derived from Streptococcus pneumoniae or a homologue thereof or an antigenic fragment of the protein or homologue, or nucleic acid coding therefor in the preparation of an agent for the prophylaxis or diagnosis of infection by S. pneumoniae, wherein the protein
has a molecular weight of about 34 kDa as determined by SDS-PAGE under reducing conditions and has the following amino terminal sequence:
V X X V G I N T X S X X Q S (Val X X Val Gly He Asn Thr X Ser X X Gin Ser) (SEQ ID NO: 1)
wherein X represents an unknown amino acid residue.
As already mentioned, the protein isolated by the inventors has been shown to be antigenic and they can therefore be used as vaccines or agents for the diagnosis of infection by S. pneumoniae.
Thus, the invention also provides a pharmaceutical or vaccine composition comprising the protein of the present invention together with a pharmaceutically acceptable excipient.
The pharmaceutical or vaccine composition may also comprise an adjuvant. Examples of adjuvants well known in the art include inorganic gels such as aluminium hydroxide or water-in-oil emulsions such as incomplete Freund's adjuvant. Other useful adjuvants will be well known to the skilled man.
The protein may be administered by a variety of routes including enteral, for example oral, nasal, buccal, topical or anal administration or parenteral administration, for example by the intravenous, subcutaneous, intramuscular or intraperitoneal routes.
The form taken by the composition and the excipients it contains will, of course, depend upon the chosen route of administration. For example, oral formulations may be in the form of syrups, elixirs, tablets or capsules, which may be enterically coated to protect the protein from degradation in the stomach. Nasal or transdermal formulations will usually be sprays or patches respectively. Formulations for injection
may be solutions or suspensions in distilled water or another pharmaceutically acceptable solvent or suspending agent.
The appropriate dosage of the protein of the present invention to be administered to a patient will be determined by a clinician. However, as a guide, a suitable dose for vaccination may be from about 5 to 100 μg when administered parenterally. However, the dosage may be 10-100 fold higher for nasal and oral administration, depending on the formulation, adjuvant, delivery system, patient profile, etc.
As mentioned above, the protein isolated by the inventors is antigenic and therefore the invention also provides an antibody which binds specifically to the protein. The antibody may be a monoclonal or a polyclonal antibody. Techniques for the preparation of both monoclonal and polyclonal antibodies are well known to those skilled in the art.
In addition to whole antibodies, the present invention includes derivatives thereof which are capable of binding to proteins etc as described herein. Thus the present invention includes antibody fragments and synthetic constructs, and the term "antibody" as used herein is intended to include these. Examples of antibody fragments and synthetic constructs are given by Dougall et al in Tibtech 12 372-379 (September 1994).
Antibody fragments include, for example, Fab, F(ab') and Fv fragments. Fab fragments (These are discussed in Roitt et al [supra] ). Fv fragments can be modified to produce a synthetic construct known as a single chain Fv (scFv) molecule. This includes a peptide linker covalently joining Vh and N regions, which contributes to the stability of the molecule. Other synthetic constructs that can be used include CDR peptides. These are synthetic peptides comprising antigen-binding determinants. Peptide mimetics may also be used. These molecules are usually conformationally restricted organic rings that mimic the structure of a CDR loop and that include antigen-interactive side chains.
Synthetic constructs include chimaeric molecules. Thus, for example, humanised (or primatised) antibodies or derivatives thereof are within the scope of the present invention. An example of a humanised antibody is an antibody having human framework regions, but rodent hypervariable regions. Ways of producing chimaeric antibodies are discussed for example by Morrison et al in PNAS, 81, 6851-6855 (1984) and by Takeda et al in Nature. 314, 452-454 (1985).
Synthetic constructs also include molecules comprising an additional moiety that provides the molecule with some desirable property in addition to antigen binding. For example the moiety may be a label (e.g. a fluorescent or radioactive label, or latex or an equivalent solid physical label such as an erythrocyte). Alternatively, it may be a pharmaceutically active agent.
Antibodies, or derivatives thereof, find use in detection diagnosis of S. pneumoniae.
Thus, in another aspect, the present invention provides a method for the detection/diagnosis of S. pneumoniae which comprises the step of bringing into contact a sample to be tested and antibodies capable of binding to one or more proteins of the invention, or to fragments thereof.
In addition, so-called "Affibodies" may be utilised. These are binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain (Nord et al,). Thus, small protein domains, capable of specific binding to different target proteins can be selected using combinatorial approaches.
Preferred features of each aspect of the invention as for each other aspect, mutatis mutandis. The disclosure of the prior art documents mentioned herein is incorporated to the fullest extent permitted by law.
The invention will now be described in greater detail with reference to the following examples and to the drawings in which:
FIGURE 1 is a flow chart with a schematic summary of the protein purification procedure used in the present invention.
FIGURE 2 is the electroelution profile from S. pneumoniae cell wall extract analysed on SDS-PAGE.
Lane 1 : coomassie stain of crude extract separated by SDS-PAGE; Lane 3: molecular mass standards;
Lanes 2 and 4-11 : proteins recovered by electroelution.
FIGURE 3 is a profile from anion exchange chromatography.
FIGURE 4 shows purified S. pneumoniae proteins of molecular masses 14, 16, 34 and
57 kDa
FIGURE 5 is a histogram showing pulmonary clearance following immunisation with S. pneumoniae protein of 16 kDa.
FIGURE 6 is a histogram showing pulmonary clearance following immunisation with S. pneumoniae protein of 34 kDa.
FIGURE 7 is a histogram showing pulmonary clearance following immunisation with S. pneumoniae protein of 57 kDa.
FIGURE 8 is a gel showing the results of a two-dimensional gel analysis of S. pneumoniae protein of 34 kDa.
FIGURE 9 is gel showing the results of a Western blot analysis of S. pneumoniae protein of 34 kDa.. Lane 1 : homologous cell wall extract Lane 2: Dimensional strip slot Lane 3: molecular weight standards in Lane 3.
Example 1 - Isolation and Purification of Antigens
Bacteria Serogroup 3 Streptococcus pneumoniae (ATCC 49619) was used to obtain antigens investigated in this study and used in homologous bacterial challenge in the animal studies. Bacterial strains were grown overnight on blood agar at 37°C and 5% CO2 or cultured in tryptic soya broth (Oxoid Ltd, Basingstoke, Hampshire, UK) overnight in a shaker incubator at 37°C.
Protein Purification
Extraction of Cell Wall Proteins
Aseptically, a loop full of S. pneumoniae was inoculated into 10 mL of sterile tryptone soya broth and cultured overnight in a 37°C shaker incubator. 2 x 5 mL aliquots were subcultured into 2 x 500 mL volumes of sterile tryptone soya broth and cultured overnight in a 37°C shaker incubator. Aseptically, a loop of bacterial suspension was removed from each culture, streaked onto blood agar and incubated overnight at 37°C in CO2 as a growth and contaminant check.
The bacterial culture was centrifuged at 18000 x g for 20 minutes at 4°C using a
Beckman J-2™ centrifuge. The pellet was washed twice in phosphate buffered saline (PBS) by centrifugation, then resuspended in 10 mL PBS and 200 μl 10% (w/v) sodium deoxycholate and stiπed at room temperature for 1 hour. The suspension was centrifuged at 27000 x g for 15 minutes at 4°C, the supernatant was recovered and stiπed while gradually adding ammonium sulphate to a final concentration of 70%
(w/v). The suspension was centrifuged at 27000 x g for 15 minutes at 4°C, the pellet redissolved in 10 mL 10 mM sodium phosphate, pH 7.0. The resuspended pellet was dialysed against 3 x IL changes of 10 mM sodium phosphate, pH 7.0 at 4°C, leaving a minimum of 2 hours between changes. The dialysed protein suspension was centrifuged for 20 minutes at 15000 rpm at 4°C, the supernatant was kept and a protein assay performed. The protein suspension was concentrated by lyophilisation and a sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis performed.
SDS-PAGE
The Protean II xi cell™ (Bio-Rad) was used to separate proteins according to their molecular weights. A discontinuous gel consisting of 12% (w/v) acrylamide/BIS separating gel and a 4% (w/v) acrylamide/BIS stacking (upper) gel was prepared from a 30% (w/v) stock solution of acrylamide/BIS (N,N'-methylenebisacrylamide) in Tris buffer. The polyacrylamide gel was polymerised using ammonium persulfate and
TEMED. The lyophilised protein extract was suspended 1 :1 (v/v) in sample buffer (0.5M Tris HC1 pH 6.8; 10% v/v) glycerol; 10% (w/v) SDS; 0.05% (w/v) bromophenol blue; 0.05% (v/v) β-mercaptoethanol), boiled for 5 minutes and then approximately 1 mL of this was loaded onto the top of the gel. Electrophoresis was performed at a constant cuπent of 16mA per gel until the dye front passed through the stacker and then increased to 24 mA for electrophoresis through the resolving gel. The average running time was between 4 and 5 hours. The separated proteins were then recovered by electroelution using the BIORAD™ flat bed electroeluter for 1 hour at 200V and a maximum of 0.2mA into 30 individual tubes. Protein composition of the recovered fractions was assessed by analytical SDS-PAGE and either Coomassie or Silver staining of proteins. Analytical SDS-PAGE was performed using a Mini- protean II ™ cell (Bio-Rad) at a constant 200V for about 45 minutes. Protein concentrations were determined using the Pierce Micro BCA™ protein assay and comparison with albumin standards.
SDS Removal from Purified Proteins
Samples containing SDS were treated with a 200μL volume of lOOmM potassium phosphate per lmL of sample and left on ice for 60 minutes. The sample was centrifuged at 10000 x g for 20 minutes at 4°C in a microcentrifuge. The supernatant was recovered and desalted by overnight dialysis against nanopure water.
Liquid Chromatography Separation Anion Exchange Liquid Chromatography The extracted proteins were additionally purified by anion exchange chromatography and separated according to their molecular charge interactions. The column (Q5 column, Bio-Rad) was equilibrated with a low salt buffer (20mM Tris-HCl, pH 8.45) at a flow rate of lmL/min for 10 minutes. Lyophilised cell wall extracts were resuspended in the same buffer to a concentration of 5mg per mL and loaded onto the column. Proteins were eluted using an increasing salt gradient by gradually increasing the proportion of 20mM Tris-HCl, 500mM sodium chloride, pH 8.6 passed through the column. Fractions were recovered, lyophilised and assessed by analytical SDS- PAGE. Fractions from multiple runs were pooled and proteins were further purified by preparative SDS-PAGE and electroelution as previously described.
Results
The methods described above successfully purified ten proteins of different molecular weights which were able to be assessed in animal immunisation studies as described in Example 3 below. The most active proteins purified had molecular masses of 12- 14kDa, 16kDa, 34kDa and 57kDa. In total, 23 different proteins were separated in yields ranging from 20 to 500μg in a 6L culture with a total protein concentration of cell wall extract of from 25-30mg. Figure 2 shows the profile of the cell wall extract and the different proteins separated by electroelution from the crude protein extract.
Not all proteins eluted from the gel as a single protein band; some fractions were composed of 2 or 3 different proteins.
Elution profile for Cell Wall Proteins Using Anion Exchange Chromatography
The elution profile from anion exchange chromatography is shown in Figure 3. The first peak represents elution of unbound proteins. The subsequent two major peaks contained most of the proteins that were eluted with increasing salt concentration. The proteins in these peaks were further purified by SDS-PAGE.
Example 2 - N-terminal Sequence Analysis
The N-terminal sequence of the proteins was determined from an excised band from an analytical SDS-PAGE. Analyses were performed by the Biomolecular Resource Unit, The John Curtin School of Medical Science (Australian Capital Teπitory, Australia).
Table 1 - Amino Acid Sequence Analysis Results of the Purified Proteins
To assist in the characterisation of the proteins, the information obtained from the partial amino acid sequence was searched through the GenBank databases to determine homology to known protein sequences. It was found that the 12-14 kDa protein has a 100% sequence homology match with that of a 12 kDa protein from S.
pneumoniae. The 16kDa protein has been found to be an isomer of the 12-14 kDa protein.
According to a study by Koberg et al, (Microbiology, 143(1), 55-61 (Jan 1997)), two monoclonal antibodies against Streptococcus pneumoniae reacted with a highly conserved epitope on eubacterial L7/L12 ribosomal proteins. A high degree of amino acid sequence homology was found across 66 eubacteria, representing 27 different species. The approximate 12-14kDa protein had a 100% sequence match with the 12 kDa protein from this study (Kolberg et al).
The 34kDa protein appears to be a novel protein as a BLAST search of publicly available databases revealed no significant similarities.
Example 3 - Mouse Lung Clearance Model Animals
Balb/c mice, 6-10 weeks old were housed and maintained in a pathogen free environment with free access to sterilised food and water.
Preparation of Live Bacteria Bacteria were grown overnight on blood agar plates at 37°C and 5% CO . The bacteria were harvested and washed twice in sterile PBS by centrifugation at 10000 x g at room temperature. The bacterial concentration was determined by optical density at 405 nm and calculated from a regression curve, the accuracy of the concentration for viable bacterial count was confirmed by titration and overnight culture.
Immunisation Regime
Mice were initially immunised on day 0 by Peyer' s patches inoculation and boosted by intratracheal administration 14 days later. On day 21, these mice were challenged with live S. pneumoniae.
Peyer's Patch Immunisation
The mice were sedated by a subcutaneous injection of 0.25 L ketamine/xylazine at a dosage of 5 mg/ml ketamine hydrochloride; 2mg/ml xylazine hydrochloride. The small intestine was exposed through a mid-line abdominal incision and the protein injected subserosal into each Peyer's patch. The immunisation protein was prepared by emulsifying 2.5μg/μL protein in a 1 :1 ratio with incomplete Freund's adjuvant (Sigma Immunochemicals, St Louis, MI, USA) and a total concentration of lOμg protein administered to each animal.
Intratracheal Inoculation of Mice
On day 14, mice received an intratracheal boost. The mice were sedated by intravenous injection with 20 mg saffan per kg of body weight. lOμg protein in PbS in a total volume of 20μL was delivered via the trachea into the lungs with a 22.1/2G catheter.
Pulmonary Challenge
On day 21, the mice received a live bacterial challenge. The mice were sedated with saffan as described above, and an inoculum of 1 x 107 CFU in 20μL of live S. pneumoniae was introduced into the lungs via the trachea as for the intratracheal boost. Five hours following the challenge, the mice were euthanased by an intraperitoneal injection of 0.2mL of sodium pentobarbital.
Blood was collected by heart puncture and the separated serum stored below-20°C prior to analysis. The trachea was exposed and the lungs were lavaged by insertion and removal of 0.5mL sterile PBS. The recovered fluid (BAL) was assessed for bacterial recovery by plating 10 fold serial dilutions onto blood agar for CFU determination. An aliquot was removed for cytospin slide preparation, staining and differential cell counts. The BAL was then centrifuged for 10 min at 1000 rpm at 4°C and the supernatant stored below -20°C until required. The pellet was resuspended in
PBS and methylene blue and the total number of white cells in the BAL were counted. The lungs were removed following lavage, placed in 2mL sterile PBS and homogenised. The lung homogenate was assessed by plating 10-fold serial dilutions onto blood agar for CFU determination. Results are presented only for the proteins which showed significant degrees of pulmonary clearance from the lungs.
Results
Three proteins assessed in immunisation and bacterial challenge showed significant degrees of pulmonary clearance from the lungs. These were proteins with molecular masses of 16, 34 and 57 kDa and identified in Table 1 above. The results of the bacterial clearance and comparison with the recovery in non-immune mice challenged at the same time are shown in Table 2 below and graphically represented in Figures 5 to 7. A fourth protein of significance was the 12-14kDa protein. This protein has been previously identified through monoclonal antibody assay (see above) as being present in a large number of bacteria. However, there is no evidence in the literature that it has been tested as a vaccine antigen.
Table 2 - Pulmonary Clearance Following Immunisation With Purified Proteins
Example 4 - Serum Antibody
Serum from mice immunised with either the 34 kDa protein or the 12-14 kDa protein was assessed for the presence of antibody to the immunising protein by ELIS A.
Method
Polysorb microtitre wells were coated with 10 μg per ml of purified protein, either 34 kDa protein or 12-14 kDa protein, in coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) by incubation with 50 μl per well overnight at 4 °C. The plates were washed 5 times in washing buffer (PBS containing 0.05% Tween-20). The wells were blocked with 100 μl of 5% Skim Milk in PBS/Tween-20 buffer for 60 min at room temperature. The plates were washed 5 times as above and 50 μl serum dilutions commencing at 1/5 were added to the wells and incubated at room temperature for 90 minutes. Following washing, the wells were incubated with anti-mouse IgG- horseradish peroxidase conjugated antisera for 90 minutes. The wells were washed and developed with TMB (tetra methylbenzidine in dimethyl sulphoxide) in phospate citrate buffer, pH 5 containing hydrogen peroxide. The reaction was stopped with 0.5 M H SO4 and the optical density of the wells read at 450 nm. The concentration of immunoglobulin in the test wells was determined by calculation from known concentrations of IgG assayed as standards on the same microtitre plate.
Results
Group Serum IgG (ng/ml)
Nonlmmune 0
34 kDa protein (10 μg) 2474
Group Serum IgG (ng/ml)
Nonlmmune 0
12-14 kDa protein (10 μg) 39
34 kDa protein (10 μg) 130
Example 5 - Preparation of 34 kDa protein for sequencing
The protean IEF Cell was used for the first dimension isoelectric focusing and for the second dimensional electrophoretic protein analysis.
Method
The first dimension electrophoresis was performed using 7cm IPG strip which was actively rehydrated overnight for 17 hours at 50V. 60uL (lug/uL) of cell wall extract and a total volume of 140uL of rehydration solution ( 8.3M urea, 2% CHAPS, 50mM Dithiothreilol, 0.1% Bio-Lytes, and 0.001% Bromocresol blue), was applied to the sample well. In the second dimension, the gel strips were overlayed onto 12% SDS- PAGE gels and a 4% stacker (as described earlier) and ran at 5mA for 1 hour and 15mA for 1.5 hours per gel strip. One of the gels was coomassie stained and is shown in Figure 8, and the other was transfeπed to a membrane for a western blot analysis as described in the methods. The _esults of the western blot are shown in Figure 9.
Results
Using the 2 Dimensional electrophoresis, the molecular weight of the 34 kDa protein was calculated to be 34.1 kDa.
Figure 8: An identified band similar to the one in figure 2 of a 34.1 kDa protein was excised from the gel. Figure 9: 34 kDa protein using specific antisera from the mice (immunisations shown previously) was detected in the homologous cell wall extract (lane 1), and the same band was also seen in the 2 Dimensional strip slot in lane 2, compared to the molecular weight standards in Lane 3.
Claims
1. A protein derived from Streptococcus pneumoniae or a homologue thereof or an antigenic fragment of the protein or homologue, wherein the protein has a molecular weight of about 34 kDa as determined by SDS-PAGE under reducing conditions and has the following amino terminal sequence:
V X X V G I N T X S X X Q S
(Val X X Val Gly He Asn Thr X Ser X X Gin Ser) (SEQ ID NO: 1);
wherein X represents an unknown amino acid residue.
A process for the preparation of an isolated and purified protein the process comprising the following steps:
(a) preparing cultures of S. pneumoniae, growing the cultures under appropriate conditions and harvesting them, followed by washing with centrifugation to yield a washed cell pellet;
(b) resuspending the washed cells in an appropriate buffer followed by disruption of the cells;
(c) centrifuging to remove cell debris and obtaining the supernatant containing soluble cell proteins;
(d) subjecting the solution obtained to anion exchange chromatography with a sodium chloride gradient elution, and pooling the fractions coπesponding to each separate peak;
(e) suspending the protein fractions in a buffer comprising 0.5M Tris HC1 pH 6.8; 10%(v/v) glycerol; 10% (w/\) SDS; 0.05% (w/v) bromophenol blue; and 0.05% (v/v) β-mercaptoethanol; boiling the mixture and then purifying by SDS-PAGE using a 12% (w/v) acrylamide/BIS separating gel with a 4% (w/v) acrylamide/BIS stacking gel, run at 16 mA in the stacking gel and 24 mA in the resolving gel;
(f) selecting a fraction containing a protein having a molecular weight of 34kDa and isolating the protein from the selected fraction.
3. Nucleic acid encoding a protein or antigenic fragment thereof as defined in claim 1 or nucleic acid complementary thereto.
4. A vector containing nucleic acid as claimed in claim 3.
5. An organism transformed with nucleic acid as claimed in claim 3.
6. A process for the preparation of a protein as claimed in claim 1, the process comprising expressing nucleic acid as claimed in claim 3.
7. A protein derived from Streptococcus pneumoniae or a homologue thereof or an antigenic fragment of the protein or homologue, or nucleic acid coding therefor, for use in medicine, particularly in the prophylaxis or diagnosis of infection by S. pneumoniae, wherein the protein has a molecular weight of about 34 kDa as determined by SDS-PAGE under reducing conditions and has the following amino terminal sequence:
V X X V G I N T X S X X Q S
(Val X X Val Gly He Asn Thr X Ser X X Gin Ser) (SEQ ID NO: 1)
wherein X represents an unknown amino acid residue.
8. A method of detecting and/or diagnosing S. pneumoniae which comprises:
(a) bringing into contact with a sample to be tested a protein or antigenic fragment as defined in claim 1 ; and
(b) detecting the presence of antibodies to S. pneumoniae.
9. The use of a protein derived from Streptococcus pneumoniae or a homologue thereof or an antigenic fragment of the protein or homologue, or nucleic acid coding therefor, in the preparation of an agent for the prophylaxis or diagnosis of infection by S. pneumoniae, wherein the protein has a molecular weight of about 34 kDa as determined by SDS-PAGE under reducing conditions and has the following amino terminal sequence:
V X X V G I N T X S X X Q S
(Val X X Val Gly He Asn Thr X Ser X X Gin Ser) (SEQ ID NO: 1)
wherein X represents an unknown amino acid residue.
10. A pharmaceutical or vaccine composition comprising a protein or antigenic fragment as defined in claim 1 together with a pharmaceutically acceptable excipient.
11. A pharmaceutical or vaccine composition as claimed in claim 10 which further comprises an adjuvant.
12. An antibody which binds specifically to a protein or antigenic fragment as defined in claim 1.
13. A method of vaccinating a subject against S. pneumoniae which comprises the step of administering to the subject an effective amount of protein or antigenic fragment as defined in claim 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9928678.3A GB9928678D0 (en) | 1999-12-03 | 1999-12-03 | Streptococcus pneumoniae antigens |
GB9928678 | 1999-12-03 | ||
PCT/GB2000/004602 WO2001040472A2 (en) | 1999-12-03 | 2000-12-01 | Streptococcus pneumoniae antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1240329A2 true EP1240329A2 (en) | 2002-09-18 |
Family
ID=10865707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00977771A Withdrawn EP1240329A2 (en) | 1999-12-03 | 2000-12-01 | i STREPTOCOCCUS PNEUMONIAE /i ANTIGENS |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1240329A2 (en) |
JP (1) | JP2003515341A (en) |
AU (1) | AU1540501A (en) |
CA (1) | CA2392895A1 (en) |
GB (1) | GB9928678D0 (en) |
WO (1) | WO2001040472A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2444133A1 (en) | 2001-04-16 | 2002-10-24 | Wyeth Holdings Corporation | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
WO2011112906A2 (en) | 2010-03-12 | 2011-09-15 | Children's Medical Center Corporation | Novel immunogens and methods for discovery and screening thereof |
JP6494527B2 (en) | 2013-02-07 | 2019-04-03 | ザ チルドレンズ メディカル センター コーポレーション | Protein antigens that provide protection from pneumococcal colonization and / or disease |
MX2021002910A (en) | 2018-09-12 | 2021-07-16 | Affinivax Inc | Multivalent pneumococcal vaccines. |
AU2022342080A1 (en) | 2021-09-09 | 2024-03-28 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474905A (en) * | 1993-11-24 | 1995-12-12 | Research Corporation Technologies | Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens |
-
1999
- 1999-12-03 GB GBGB9928678.3A patent/GB9928678D0/en not_active Ceased
-
2000
- 2000-12-01 CA CA002392895A patent/CA2392895A1/en not_active Abandoned
- 2000-12-01 EP EP00977771A patent/EP1240329A2/en not_active Withdrawn
- 2000-12-01 AU AU15405/01A patent/AU1540501A/en not_active Abandoned
- 2000-12-01 WO PCT/GB2000/004602 patent/WO2001040472A2/en not_active Application Discontinuation
- 2000-12-01 JP JP2001542537A patent/JP2003515341A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO0140472A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2392895A1 (en) | 2001-06-07 |
JP2003515341A (en) | 2003-05-07 |
WO2001040472A3 (en) | 2002-03-14 |
AU1540501A (en) | 2001-06-12 |
GB9928678D0 (en) | 2000-02-02 |
WO2001040472A2 (en) | 2001-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100143415A1 (en) | Streptococcus Pneumoniae Antigens | |
EP0835313B1 (en) | Omp26 antigen from haemophilus influenzae | |
CN109456393B (en) | Application of streptococcus pneumoniae protein in resisting streptococcus pneumoniae infection | |
Blanco et al. | Porin activity and sequence analysis of a 31-kilodalton Treponema pallidum subsp. pallidum rare outer membrane protein (Tromp1) | |
JPH11501809A (en) | Antigen composition for mycoplasma | |
US7517533B2 (en) | Pseudomonas aeruginosa antigens | |
US20090246228A1 (en) | Moraxella catarrhalis Proteins | |
WO2001040472A2 (en) | Streptococcus pneumoniae antigens | |
JP2009029825A (en) | Antigen | |
US20050048077A1 (en) | Compositions, test kits and methods for detecting helicobacter pylori | |
US6248583B1 (en) | Chromosomally-encoded membrane protein of borrelia burgdorferi | |
US20030166027A1 (en) | Compositions, test kits and methods for detecting helicobacter pylori | |
NZ541257A (en) | 14 kDa Moraxella Catarrhalis protein | |
MXPA00011069A (en) | Moraxella catarrhalis proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020703 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030701 |